The Second Generation Sulfonylureas: Glipizide and Glyburide
1985
Baker, Danial E. | Campbell, Keith (R. Keith)
Glyburide and glipizide are approved by the FDA for treatment of symptomatic and asymp tomatic NIDDM patients in whom hyperglycemia cannot be satisfactorily controlled by diet and exercise. Pharmacology studies suggest that glyburide and glipizide sensitize the beta cells of the pancreas to release insulin only in the presence of elevated serum glucose levels. Long-term efficacy appears to depend on extrapancreatic effects, suppressing hepatic glucose production, and improved postreceptor insulin activity.
显示更多 [+] 显示较少 [-]AGROVOC关键词
书目信息
Diabetes educator
卷
11
期
3
页码
29
- 36
ISSN
0145-7217
出版者
Sage Publications
其它主题
Glipizide; Noninsulin-dependent diabetes mellitus
语言
英语
类型
Journal Article; Text
2024-02-28
MODS